Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05190445 · ClinicalTrials.gov registry record · Phase 2
Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma
A Phase 2 study of HER2-positive Gastric Cancer, sponsored by Pieris Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 5
- Study locations
NCT05190445 is a Phase 2 study of HER2-positive Gastric Cancer that is active but no longer recruiting, run by Pieris Pharmaceuticals. The registered enrollment target is 80 participants, below the 318-participant average among 6 other HER2-positive Gastric Cancer trials with a reported enrollment target (75% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT05190445, a Phase 2 study of HER2-positive Gastric Cancer, is active but no longer recruiting, sponsored by Pieris Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 5
- Study locations
Study Summary
A Phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel in patients with HER2-high and in combination with tucatanib in patients with HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Conditions Studied
Interventions
- DRUG Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel
- DRUG Cinrebafusp alfa (PRS-343) in combination with tucatinib
Study Locations (5)
California
- Sansum Clinic - Santa Barbara
Maryland
- Maryland Oncology-Hematology - Silver Spring
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- University of Texas MD Anderson Cancer Center - Houston
Other
- Samsung Medical Center - Seoul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2023-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05190445
The ClinicalTrials.gov registry entry for NCT05190445 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 318-participant average among 6 other HER2-positive Gastric Cancer trials with a reported enrollment target (75% lower). The listed sponsor is Pieris Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HER2-positive Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel is the first listed.
NCT05190445 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Maryland, New York.
Frequently Asked Questions
What is clinical trial NCT05190445 about?
NCT05190445 is a clinical study titled "Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma". A Phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel in patients with HER2-high and in combination with tucatanib in patients with HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma.
What is the current status of trial NCT05190445?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2021-11-01. Estimated completion is 2023-02-01.
What conditions does trial NCT05190445 study?
This clinical trial studies the following conditions: HER2-positive Gastric Cancer.
What interventions are being tested in trial NCT05190445?
The interventions under investigation include: Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel (DRUG), Cinrebafusp alfa (PRS-343) in combination with tucatinib (DRUG).
Who is sponsoring clinical trial NCT05190445?
This trial is sponsored by Pieris Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05190445 being conducted?
This trial has 5 study locations across California, Maryland, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-positive Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
RECRUITING · Phase 3
-
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
RECRUITING · Phase 1
-
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
RECRUITING · Phase 3
-
HER-2 B Cell Peptide Vaccine
RECRUITING · Phase 1
-
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
ACTIVE NOT RECRUITING · Phase 1
-
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.